UnitedHealthcare Knee Surgery Coverage Update

Coverage and Medical Necessity Criteria

InterQual-based medical necessity

Covered when medical necessity criteria are met per InterQual

InterQual referenced coverage: Coverage for knee surgery (arthroscopy, arthrotomy, total joint replacement, unicondylar/patellofemoral replacement) is determined by the InterQual clinical criteria listed in the policy.refer to InterQual

See policy for specific InterQual modules: Arthroscopy or Arthroscopically Assisted Surgery, Knee; Arthroscopy, Diagnostic; Arthrotomy, Knee; Total Joint Replacement (TJR), Knee; Unicondylar or Patellofemoral Knee Replacement.

Articular cartilage repair — unproven / not medically necessary

Not medically necessary / unproven for articular cartilage repair technologies when evidence is insufficient

Unproven cartilage repair methods: The following articular cartilage repair techniques and products are considered unproven and not medically necessary due to insufficient evidence of efficacy: autologous minced or particulated cartilage (e.g., Cartilage Autograft Implantation System, Reveille Cartilage Processor); allogeneic minced or particulated cartilage (e.g., BioCartilage, DeNovo NT/ET); Collagen Meniscus Implant; decellularized osteochondral allografts (e.g., Chondrofix); reduced osteochondral discs (e.g., ProChondrix, Cartiform); synthetic resorbable polymers (e.g., PolyGraft BGS, TruFit, TruGraft); and xenograft implantation.insufficient evidence

Policy lists examples and products; clinical studies cited show case series, small cohorts, and animal data with limited comparative or long-term results.

Evidence sufficiency requirement

Coverage stance informed by available evidence

General evidence-based conditions: Coverage decisions for novel cartilage and meniscal implants require demonstration of clinically meaningful benefit in comparative studies with adequate sample size and follow-up, and acceptable failure rates; many technologies cited lack randomized controlled trials or long-term outcome data.evidence of comparative effectiveness and acceptable failure rates

Evidence summaries report small case series, single-arm studies with short follow-up, animal data, and high early failure rates for some implants (e.g., decellularized osteochondral allograft plugs).

The policy explicitly lists the specific articular cartilage repair techniques and products that are considered unproven and therefore not supported for coverage due to insufficient evidence of efficacy. Examples include: autologous minced or particulated cartilage (e.g., Cartilage Autograft Implantation System, Reveille Cartilage Processor); allogeneic minced or particulated cartilage (e.g., BioCartilage®, DeNovo NT, DeNovo ET); Collagen Meniscus Implant (CMI); decellularized osteochondral allografts (e.g., Chondrofix); reduced osteochondral discs (e.g., ProChondrix, Cartiform); synthetic resorbable polymers (e.g., PolyGraft BGS, TruFit, TruGraft); and xenograft implantation.

Certain technologies are highlighted because available studies report high early failure rates or otherwise insufficient clinical evidence. For example, literature on decellularized osteochondral allograft plugs documents implant delamination and notably high early failure (one case series reported a 29% revision rate and another reported a 72% failure rate within the first 2 years). Evidence for reduced osteochondral allograft discs is limited to small case series with short follow-up and is insufficient to support routine coverage.

Because robust comparative evidence demonstrating clinically meaningful benefit is lacking for the listed products and techniques, the policy states that these interventions are unproven and not medically necessary for treating individuals with articular cartilage defects. This stance applies to the listed technologies (see examples above) across treated indications unless convincing comparative data with adequate follow-up are provided.

The policy basis emphasizes a consistent lack of adequate comparative evidence — specifically the absence of randomized controlled trials and long-term outcome data — for many of these cartilage repair approaches. Case series and small single-arm studies (including reports on BioCartilage and particulated juvenile articular cartilage products) may show short-term improvements compared with baseline but are at high risk of bias and do not establish superiority or durability. Larger randomized controlled trials with sufficient follow-up are needed to evaluate comparative effectiveness and long-term graft durability before coverage can be supported.

Applicable Billing and Procedure Codes

Applicable CPT codes (selection)CPT

0737T	Xenograft implantation into the articular surface.
27412	Autologous chondrocyte implantation, knee.
27415	Osteochondral allograft, knee, open.
27416	Osteochondral autograft(s), knee, open (e.g., mosaicplasty) (includes harvesting of autograft[s]).
27418	Anterior tibial tubercleplasty (e.g., Maquet type procedure).
27437	Arthroplasty, patella; without prosthesis.
27438	Arthroplasty, patella; with prosthesis.
27440	Arthroplasty, knee, tibial plateau.
27441	Arthroplasty, knee, tibial plateau; with debridement and partial synovectomy.
27442	Arthroplasty, femoral condyles or tibial plateau(s), knee.

1–10 of 18

1/2

Applicable arthroscopy CPT codesCPT

29866	Arthroscopy, knee, surgical; osteochondral autograft(s) (e.g., mosaicplasty) (includes harvesting of the autograft[s]).
29867	Arthroscopy, knee, surgical; osteochondral allograft (e.g., mosaicplasty).
29868	Arthroscopy, knee, surgical; meniscal transplantation (includes arthrotomy for meniscal insertion), medial or lateral.
29870	Arthroscopy, knee, diagnostic, with or without synovial biopsy (separate procedure).
29871	Arthroscopy, knee, surgical; for infection, lavage and drainage.
29873	Arthroscopy, knee, surgical; with lateral release.
29874	Arthroscopy, knee, surgical; for removal of loose body or foreign body (e.g., osteochondritis dissecans fragmentation, chondral fragmentation).
29875	Arthroscopy, knee, surgical; synovectomy, limited (e.g., plica or shelf resection) (separate procedure).
29876	Arthroscopy, knee, surgical; synovectomy, major, 2 or more compartments (e.g., medial or lateral).
29877	Arthroscopy, knee, surgical; debridement/shaving of articular cartilage (chondroplasty).

1–10 of 21

1/3

Applicable HCPCS/other codesHCPCS

G0428	Collagen meniscus implant procedure for filling meniscal defects (e.g., CMI, collagen scaffold, Menaflex).
J7330	Autologous cultured chondrocytes, implant.
S2112	Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells).

Radiographic findings for severe osteoarthritis

Accepted radiographic criteriaUnitedHealthcare will accept three or more moderate to severe radiographic findings (narrowing of joint space, osteophyte formation, subchondral sclerosis, subchondral cysts, deformity of bony end-plates, or thinning/complete loss of articular cartilage) to support a diagnosis of severe osteoarthritis.

Examples of radiographic findingsNarrowing of joint space; osteophyte formation; subchondral sclerosis; subchondral cysts; deformity of bony end-plates; thinning or complete loss of articular cartilage.

Context for useThese radiographic findings are used to substantiate severity when applying InterQual-based medical necessity criteria for knee surgery.

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization and FDA/Tissue Documentation

Prior authorization is required for procedures described in this policy. When requested, documentation must include device/product identification and, for donor-derived tissue products, the tissue establishment registration information and donor screening/testing per FDA HCT/P requirements.

Submit prior authorization requests before the procedure date per payer rules
Include device and product names, manufacturer, model/catalog/lot numbers when applicable
For donor-derived tissue products (eg, DeNovo NT), include tissue establishment FDA registration/license number and donor screening/testing documentation

Denial Risk

Documentation-Related Denial Risk

Failure to provide complete medical records, required imaging reports, labeled diagnostic images via the external portal, laboratory results, or prior therapy documentation may result in denial of the request.

Clinical Background and Rationale

Articular cartilage has limited intrinsic healing capacity, and focal chondral or osteochondral defects can cause pain, swelling, and functional limitation. A range of surgical and biologic approaches are under investigation to restore cartilage structure and function, including microfracture with adjuncts (e.g., BioCartilage), single-stage autologous minced cartilage implantation, autologous chondrocyte implantation, osteochondral autograft or allograft transplantation, synthetic resorbable polymer scaffolds, decellularized or reduced osteochondral allografts, collagen scaffolds (CMI), and xenograft-derived implants. While some early case series report symptomatic or functional improvement, many techniques lack randomized comparative trials and long-term outcome data, and some (for example, decellularized osteochondral plugs) have demonstrated high early failure rates. Given these limitations, clinical decision-making and coverage determinations rely on established standards (e.g., InterQual criteria) and require evidence of clinically meaningful benefit and acceptable durability for novel cartilage repair technologies.

Key Definitions and Terms

BioCartilage

DefinitionBioCartilage: an extracellular matrix consisting of cartilage allograft intended to provide a scaffold for microfracture defects; small particles are mixed with a blood solution to create a paste-like consistency applied over a cartilage defect.

Typical useApplied over a prepared microfracture defect as a paste-like scaffold to support cartilage repair.

Evidence notePolicy lists BioCartilage among articular cartilage repair technologies considered unproven or not medically necessary when evidence is insufficient.

Cartilage Autograft Implantation System

DefinitionCartilage Autograft Implantation System: a single-stage treatment that harvests minced autograft cartilage and disperses chondrocytes on a scaffold for implantation.

Procedure characteristics

OpenPayer

Surgery of the Knee (Nebraska)

Coverage and Medical Necessity Criteria

Applicable Billing and Procedure Codes

Prior Authorization, Documentation, and Provider Requirements

Clinical Background and Rationale

Key Definitions and Terms